FDA
-
-
-
-
-
-
-
Lantheus completes sale of SPECT business to SHINE Technologies
-
-
-
-
-
-
-
Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease
-
-
-
-
-
-
-
Lantheus completes Life Molecular Imaging acquisition, names new R&D head
-
-
-
-
-
-
-
Lantheus Announces Sale of SPECT Business to SHINE Technologies
-
-
-
-
-
-
-
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
-
-
-
-
-
-
-
Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
-
-
-
-
-
-
-
Lantheus’ AI-Enabled aPROMISE Now Available on Siemens Healthineers’ syngo.via platform
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

